Literature DB >> 18579244

Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation.

Muhammad Azrif1, Nicholas J Slevin, Andrew J Sykes, Ric Swindell, Beng K Yap.   

Abstract

INTRODUCTION: Post-operative residual disease in differentiated thyroid cancer is an indication for external beam radiotherapy (EBRT) especially if there is poor radioiodine uptake by the residual disease. There are no standardized guidelines or consensus in target delineation for radiotherapy in thyroid cancer. AIMS: To determine the pattern of recurrence in patients with well differentiated thyroid cancer who received adjuvant or definitive radiotherapy as well as radioiodine ablation following surgery or biopsy with a view to better defining future target volume delineation for radiotherapy.
MATERIALS AND METHODS: Forty-nine patients with differentiated thyroid cancer received radical external beam radiotherapy and radioiodine ablation (3.5GBq) following thyroidectomy or biopsy between 1990 and 2000. Nineteen patients had macroscopic residual (11) or inoperable disease (8), whilst 30 patients had clear (5) or microscopic positive resection margin (24), and 1 patient the resection margin status was unknown. All the patients were deemed high risk for local recurrence or progressive disease. The thyroid bed and regional nodes were irradiated using two radiotherapy techniques: (1) non co-planar lateral fields (NCLF) in coronal plane using 6MV photons to a dose of 45-50Gy in 16 fractions over 22 days and (2) anterior-posterior parallel pair of 6MV photons to a dose of 40-42.5Gy in 16 fractions over 22 days. There was no attempt to irradiate the lymph nodes in that part of the anterior and posterior mediastinum extending from the brachiocephalic veins to the carina.
RESULTS: The median follow-up was 5.4 years (range 0.9-12.4 years). The actuarial 5-year cause-specific survival and local control for the whole group was 75.7% and 81.4%, respectively. Of the 4 patients with mediastinal recurrence, all had neck recurrences and two had distant metastases. All the medisastinal recurrences occurred in superior mediastinum (level VII) and all were treated with NCLF in coronal plane radiotherapy technique. Furthermore, mediastinal recurrences did not occur in isolation. The 5-years loco-regional control rate was 89.1% for those with clear or microscopic positive margins and 69.2% for those with macroscopic residual or inoperable disease. Five-year cause specific survival was 58.3% for patients with macroscopic residual or inoperable disease and 91.4% for those with clear or microscopic positive margins.
CONCLUSION: The status of postoperative margin relating to bulk of disease influences local control and cause specific survival. Surgical resection in locally advanced thyroid cancer should be performed by an experienced surgeon to achieve macroscopic clearance where possible. The majority of recurrences were loco-regional. The few superior mediastinal recurrences did not occur in isolation. All the mediastinal recurrences occurred in the superior mediastinum (level VII). We recommend the target volume should encompass the thyroid bed and regional neck nodes and the superior mediastinum level VII excluding the lymph nodes on both sides of the trachea within the anterior and posterior mediastinum extending from the brachiocephalic veins to the carina (compartment 4). Thus, this should facilitate dose escalation to improve loco-regional control and avoiding radiation induced mediastinal toxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18579244     DOI: 10.1016/j.radonc.2008.05.023

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  8 in total

1.  Patterns of failure in anaplastic and differentiated thyroid carcinoma treated with intensity-modulated radiotherapy.

Authors:  H Vulpe; J Y Y Kwan; A McNiven; J D Brierley; R Tsang; B Chan; D P Goldstein; L W Le; A Hope; M Giuliani
Journal:  Curr Oncol       Date:  2017-06-27       Impact factor: 3.677

Review 2.  Standard and emerging therapies for metastatic differentiated thyroid cancer.

Authors:  Christine J O'Neill; Jennifer Oucharek; Diana Learoyd; Stan B Sidhu
Journal:  Oncologist       Date:  2010-02-08

3.  The effect of external beam radiotherapy volume on locoregional control in patients with locoregionally advanced or recurrent nonanaplastic thyroid cancer.

Authors:  Tae Hyun Kim; Ki-Wook Chung; You Jin Lee; Chan Sung Park; Eun Kyung Lee; Tae Sung Kim; Seok Ki Kim; Yoo Seok Jung; Jun Sun Ryu; Sang Soo Kim; Kwan Ho Cho; Kyung Hwan Shin
Journal:  Radiat Oncol       Date:  2010-08-06       Impact factor: 3.481

4.  Dosimetric comparison between helical tomotherapy and volumetric modulated arc-therapy for non-anaplastic thyroid cancer treatment.

Authors:  Jonathan Khalifa; Laure Vieillevigne; Sabrina Boyrie; Monia Ouali; Thomas Filleron; Michel Rives; Anne Laprie
Journal:  Radiat Oncol       Date:  2014-11-26       Impact factor: 3.481

5.  The role of adjuvant external beam radiation therapy for papillary thyroid carcinoma invading the trachea.

Authors:  Young Suk Kim; Jae Hyuck Choi; Kwang Sik Kim; Gil Chae Lim; Jeong Hong Kim; Ju Wan Kang; Hee-Sung Song; Sang Ah Lee; Chang Lim Hyun; Yunseon Choi; Gwi Eon Kim
Journal:  Radiat Oncol J       Date:  2017-06-30

6.  Neutron radiation therapy for advanced thyroid cancers.

Authors:  Tobias R Chapman; George E Laramore; Stephen R Bowen; Peter F Orio
Journal:  Adv Radiat Oncol       Date:  2016-05-25

7.  Locoregional disease control after external beam radiotherapy in 91 patients with differentiated thyroid carcinoma and pT4 tumor stage - a single institution experience.

Authors:  Nikola Besic; Marta Dremelj; Gasper Pilko
Journal:  Radiol Oncol       Date:  2018-09-22       Impact factor: 2.991

8.  Initial Experience with Proton Beam Therapy for Differentiated Thyroid Cancer.

Authors:  Nathan Y Yu; Aditya Khurana; Daniel J Ma; Michelle A Neben-Wittich; Michael A Golafshar; Lisa A McGee; Jean-Claude M Rwigema; Robert L Foote; Samir H Patel
Journal:  Int J Part Ther       Date:  2021-06-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.